LIG4- SCID autosomal recessive Phenotype MIM:600802
LIG4 deficiency was first reported in a patient in 1990 (Plowman et al., PMID: 2400879). A fibroblast line from the patient was further investigated and identified mutated DNA LIG4 in relation to autosomal recessive SCID in 1999(Riballo et al., PMID 10395545). Since this first case was described, 27 further cases have been published with a broad spectrum of clinical features ranging from Microcephaly, developmental delay, lymphopenia, and other features. LIG4 is part of a end joining mechanism required in repairing DNA double stranded breaks. It is universally expressed and required to avert apoptosis and mutagenesis. DNA LIG4 also is involved in repairing programmed DNA double stranded breaks during lymphocyte receptor development. Evidence supporting this gene-disease relationship includes case-level and experimental data. Variants have been reported in 12 cases globally with combined immunodeficiency with T- and B- Lymphocytopenia, in at least 7 publications(PMID: 31604460, PMID 11779494, PMID 17224058, PMID 16088910, PMID 27063650, PMID 16358361, PMID 24123394). Probands described range in age of onset between 3 months to 48 years. The clinical manifestation of immunodeficiency may be due to a accumulation of DNA double-strand break which would lead to progressive apoptosis in lymphocyte progenitors of LIG4 patients based on the reduction of lymphocytes over time(PMID: 23722522). A family with three affected siblings showed varying cellular and molecular phenotypes with only one truly affected sibling suggesting the phenotype can dramatically vary(PMID: 27063650). This gene-disease association is supported by mouse models, functional alteration, and expression studies(PMID: 2013615, PMID:24889605, PMID: 109119933, PMID:11779494). Complete knockout of LIG4 in mice is embryological lethal and mutations described in humans are hypomorphic, leading to significantly impaired Non-homologous end joining but still maintaining some activity( PMID: 10911993).
In summary, LIG4 is definitively associated with autosomal recessive, severe combined immunodeficiency disease and combined immunodeficiency. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time
The GenCC data are available free of restriction under a CC0 1.0 Universal (CC0 1.0) Public Domain Dedication. The GenCC requests that you give attribution to GenCC and the contributing sources whenever possible and appropriate. The accepted Flagship manuscript is now available from Genetics in Medicine (https://www.gimjournal.org/article/S1098-3600(22)00746-8/fulltext).
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. The GenCC does not independently verify the submitted information. Though the information is obtained from sources believed to be reliable, no warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, reliability or usefulness of any information. This disclaimer applies to both isolated and aggregate uses of the information. The information is provided on an "as is" basis, collected through periodic submission and therefore may not represent the most up-to-date information from the submitters. If you have questions about the medical relevance of information contained on this website, please see a healthcare professional; if you have questions about specific gene-disease claims, please contact the relevant sources; and if you have questions about the representation of the data on this website, please contact gencc@thegencc.org.